U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10774033	
	Filing Date		2004-02-06	
	First Named Inventor Shaw		awn L. Elahee	
	Art Unit		2189	
	Examiner Name	Behzad Peikari		
	Attorney Docket Numb	er	5760-20600	

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	6535998		2003-03-18	Cabrera, et al.	
	2	6729011		2001-08-21	Muhleslein	
If you wisi	h to a	dd additional U.S. Pater	nt citatio	n information pl	lease click the Add button.	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					
If you wisi	h to a	dd additional U.S. Publi:	shed Ap	plication citation	n information please click the Ad	d button.
				FOREIGN PAT	TENT DOCUMENTS	
- 1			-		Name of Patente	Pages,Columns,Lines

If you wish to add additional Foreign Patent Document citation information please click the Add button

Country

Code2 i

NON-PATENT LITERATURE DOCUMENTS

Kind Publication

Code⁴ Date

Name of Patentee or

Applicant of cited

Document

where Relevant

Figures Appear

Passages or Relevant

Examiner Cite

Initial* No Number³

Foreign Document

Examiner Initials*	Cite No	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, c(t) and/or country where publisher	Тs	
	1			

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTID Petent Documents at year, USPTID, GOV or MPEP 901.64. Either office that issued the document, by the two-letter code (WIPD Standard ST.3). The dispenses petent obcoursets, be indicated on the year of the Emporarized proteins be seen in under of the Person of the Emporarized proteins are inclinated in Codument. In a dispension of the year of the Emporarized proteins are inclinated on the document under WIPD Standard ST.16 if possible. Applicant is to piece a check mark here it English integrages the related on is attached.

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10774033	
Filing Date		2004-02-06	
First Named Inventor	Shawn L. Elahee		
Art Unit		2189	
Examiner Name	Behz	zad Peikari	
Attorney Docket Number		5760-20600	

CERTIFICATION STATEMENT

Diagon con 37	CED .	1 07 and 1	1.98 to make the	annronriata	ealaction(e)

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. Sea 37 CFR 197(a)(1)

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a training parter office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. Sea 7 CFR 1.97(c)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Lawrence J. Merkel/	Date (YYYY-MM-DD)	2007-02-05
Name/Print	Lawrence J. Merkel	Registration Number	41191

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fined by the USPTO to process) an application. Confidentially is gowered by \$5.1.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. These will vary dependential upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Trademark Office, u.S. Operatment of Commence, P. 0. Box 1450, Alexandri, V.S. 22313-1450. DNO TS END FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. Box 1450, Alexandria, VA. 22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. 2-95-79) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is SS U.S.C. 2(b)(2); (2) furnishing of the information solicided is voluntary, and (3) the principal purpuses for which the information is used by the U.S. Patient and Trademark Office is to process and/or examine you submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine you submission related to a patient agricultant or patient. If you do not furnish the requested required to the processing of the patient o

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act
 (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the
 Department of Justice to determine where the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodistrions.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the sublect matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursulant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designe, cuting an inspection of records concluded by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4 U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make.
- 3. A record from this system of records may be disclosed, as a routine use, be the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public insepticions or an insuce of partner.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.